Connor, Clark & Lunn Investment Management (CC&L)’s UroGen Pharma URGN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,188	Closed	-$243K	–	1709
2024 Q1	$243K	Sell	16,188 -29,789	-65%	-$487K	﹤0.01%	1342
2023 Q4	$690K	Buy	45,977 +16,211	+54%	+$210K	﹤0.01%	963
2023 Q3	$417K	Buy	29,766 +8,260	+38%	+$133K	﹤0.01%	1064
2023 Q2	$223K	Buy	+21,506	New	+$237K	﹤0.01%	1171

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s URGN Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 16,188 shares — an estimated $243K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in URGN in Q2 2023 and held it in 4 quarters. The position peaked at $690K in Q4 2023. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 16,188 UroGen Pharma shares in Q2 2024, an estimated $243K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in UroGen Pharma in Q2 2023 and held it in 4 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s UroGen Pharma position peaked at $690K in Q4 2023.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.